Clinical Trial Update: Durvalumab in Combination With Docetaxel, Cisplatin and 5-FU for Locally Advanced Head and Neck Squamous Cell Carcinoma [Phase 1]

View source ↗

Summary

Phase 1 study evaluating durvalumab in combination with docetaxel, cisplatin, and 5-fluorouracil for locally advanced head and neck squamous cell carcinoma has …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Head and Neck Squamous Cell Carcinoma

Drugs mentioned

• 5-Fluorouracil (5-FU)
• CISPLATIN (cisplatin)
• DOCETAXEL (DOCETAXEL)
• Durvalumab (durvalumab)

Snippet

Sponsor: Gustave Roussy, Cancer Campus, Grand Paris | Conditions: Head and Neck Cancers | Phase 1 | Status: TERMINATED